ixazomib (Ninlaro)

Indications

• treatment of multiple myeloma in patients who have received at least one prior therapy
• approved in combination with lenalidomide & dexamethasone

Dosage

oral capsule: 2.3 mg, 3 mg, 4 mg

Adverse effects

• most common
  • nausea/vomiting. diarrhea, constipation
  • thrombocytopenia
  • peripheral neuropathy
  • peripheral edema
  • back pain

Mechanism of action

• proteasome inhibitor

More general terms

• small inhibitory antineoplastic agent (ib drug)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=25183872